Pharmasset, Inc. (VRUS)

S&P 500: 1,242.31
Change: 0.44%

A clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

Recs

Avatar cashsage (24.59) Submitted: 7/03/08 1:50 PM : Start Price: $18.69 VRUS Score: -9.28

VRUS is one of the companies with a too high valuation compared to its sales potential.

Featured Broker Partners